Guggenheim Names Eyepoint Its Top Biotech Pick, Assigns $68 Price Target
Guggenheim has selected Eyepoint Pharmaceuticals Inc as its preferred investment in the biotech sector, assigning a $68 price target based on a sum-of-the-parts net-present-value analysis. The firm’s thesis rests on upcoming clinical catalysts in retinal disorders, including Phase III LUGANO topline data expected in August 2026 and a LUCIA readout …